Classroom engagement scores in digital gradebooks predicted substance use by eighth grade better than GPA (cross-validated AUC, 0.79 vs 0.63).
|Articles|May 19, 2016
Impact of probiotics on C diff-associated diarrhea (VIDEO)
For Contemporary Pediatrics, Dr Bobby Lazzara explains key findings from a meta-analysis published in the International Journal of General Medicine. The analysis examined whether probiotics were effective at reducing or preventing Clostridium difficile-associated diarrhea.
Advertisement
For Contemporary Pediatrics, Dr Bobby Lazzara explains key findings from a meta-analysis published in the International Journal of General Medicine. The analysis examined whether probiotics were effective at reducing or preventing Clostridium difficile-associated diarrhea.
Advertisement
Related to this article
Children living more than 60 miles from their surgical hospital had higher complication odds and longer stays after common procedures.
Emily Becker, MD, discusses the role of AhR agonists, skin barrier function, and steroid-free treatment options for pediatric atopic dermatitis.
Post hoc data show cariprazine improved both manic and depressive symptoms through 52 weeks in youth aged 10 to 17 years with bipolar I disorder.
CDC data show pediatric CP-CRE incidence rose 92% from 2019 to 2024, driven by NDM-CRE, mostly in children with complex medical needs.
Julie Sweetland, PhD, shares strategies to improve vaccine conversations by explaining the science, acknowledging parental concerns, and building trust.
A meta-analysis of 52 studies links NO2, SO2, and particulate matter to more pediatric atopic dermatitis visits and higher prevalence.
FDA is investigating tumor reports after Zolgensma for SMA, including 2 confirmed cases of vector integration near the GLI1 oncogene.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
How pediatricians can reframe vaccine conversations
2
Exploring AhR agonists in pediatric atopic dermatitis
3
Cariprazine improves mania and depression in pediatric bipolar I
4
FDA investigates malignancy risk with SMA gene therapy Zolgensma
5